Review of topiramate: An antiepileptic for the treatment of alcohol dependence

Current Drug Abuse Reviews

Volumn 2, Issue 2, 2009, Pages 135-142

  Kenna, George A ^a   Lomastro, Tonya L ^b   Schiesl, Allison ^b   Leggio, Lorenzo ^a   Swift, Robert M ^a,c  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acamprosate; Alcohol dependence; Disulfiram; Naltrexone; Pharmacotherapy; Topiramate

Indexed keywords

ACAMPROSATE; ACETAZOLAMIDE; ALCOHOL; ALDEHYDE DEHYDROGENASE; AMPA RECEPTOR; BARBITURIC ACID DERIVATIVE; BETA ENDORPHIN; BOSENTAN; CARBAMAZEPINE; CARBONATE DEHYDRATASE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DELAVIRDINE; DEPOTREX; DICLOFENAMIDE; DISULFIRAM; DOPAMINE; GLUTAMIC ACID; IMATINIB; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALTREXONE; OPIATE; PHENYTOIN; PLACEBO; SORAFENIB; TOPIRAMATE; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; DRUGS USED IN THE TREATMENT OF ADDICTION; FRUCTOSE;

ALCOHOL WITHDRAWAL; ALCOHOLISM; ANOREXIA; ANXIETY; ATAXIA; ATTENTION DISTURBANCE; BEHAVIOR THERAPY; BRAIN DISEASE; CHOLELITHIASIS; CLINICAL TRIAL; COCHRANE LIBRARY; CONCENTRATION LOSS; CONVULSION; DIARRHEA; DIPLOPIA; DIZZINESS; DOPAMINE RELEASE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPHASIA; EFFECT SIZE; EMBASE; ENZYME INHIBITION; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEALTH CARE AVAILABILITY; HUMAN; HYPERAMMONEMIA; INHIBITION KINETICS; INJURY; INSOMNIA; MEDICAL DECISION MAKING; MEDLINE; MEMORY DISORDER; MOTIVATION; MYALGIA; MYOPIA; NAUSEA; NEPHROLITHIASIS; NERVE CELL EXCITABILITY; NERVOUSNESS; PARESTHESIA; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PSYCHOMOTOR RETARDATION; PSYCHOSOCIAL CARE; PSYCINFO; QUALITY OF LIFE; RECEPTOR DOWN REGULATION; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SIDE EFFECT; SINUSITIS; SOCIAL PSYCHOLOGY; SOCIOECONOMICS; SOMNOLENCE; TASTE AVERSION; TREATMENT OUTCOME; UNITED STATES; WITHDRAWAL SYNDROME; DRINKING BEHAVIOR;

ALCOHOL DETERRENTS; ALCOHOL DRINKING; ALCOHOL-INDUCED DISORDERS; ALCOHOLISM; ANTICONVULSANTS; FRUCTOSE; HUMANS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 70349523723     PISSN: 18744737     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874473710902020135     Document Type: Review

References (50)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (Text Revision). Washington, D.C.: American Psychiatric Association; 2000.
2. Kenna GA, McGeary JE, Swift RM. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1. Am J Health-Syst Pharm 2004; 61: 2272-9.
3. Finney JW, Hahn AC, Moos RH. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction 1996; 91: 1773-96.
4. Grant BF, Dawson DA, Stinson FS, et al. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 2004; 74: 223-34.
5. Harwood H. Updating estimates of the economic costs of alcohol abuse in the United States: estimates, update methods and data. National Institute on Alcohol Abuse and Alcoholism. Bathesda, MD: National Institutes of Health; 1998.
6. Grant BF. Prevalence and correlates of alcohol use and DSM-IV alcohol dependence in the United States. J Stud Alcohol 1997; 58: 464-73.
7. Johnson BA. Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study. Alcohol Clin Exp Res 2004; 28: 1137-44.
8. Swift RM. Topiramate for the treatment of alcohol dependence: initiating abstinence. Lancet 2003; 361: 1666-7.
9. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361: 1677-85.
10. Volchow ND, Wang GJ, Begleiter H, et al. High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors. Arch Gen Psychiatry 2006; 63(9): 999-1008.
11. Littleton JM, DeWitte P, Litten R, et al. Challenges to medications development in treating alcohol dependence: an international perspective. Alcohol Alcohol 2004; 39: 271-5.
12. Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 2006; 111: 855-76.
13. Cloninger CR. Neurogenetic adaptive mechanisms in alcoholism. Science 1987; 236: 410-6.
14. Johnson BA. Serotonergic agents and alcoholism treatment: rebirth of the subtype concept-an hypothesis. Alcohol Clin Exp Res 2000; 24: 1597-601.
15. Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD001867. DOI: 10.1002/14651858.CD001867. pub2.
16. Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 2007; 64(9): 1069-77.
17. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293(13): 1617-25.
18. Johnson BA. Update on neuropharmalogical treatments for alcoholism: Scientific basis and clinical findings. Biochem Pharmacol 2008; 1: 75(1): 34-56.
19. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psych Res 2006; 40: 383-93.
20. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA 2006; 295: 2003-17.
21. Jonas JM, Chabac S. Letter to the Editor. JAMA 2006; 296(14): 1727.
22. Kiefer F, Mann K. Letter to the Editor. JAMA 2006; 296(14): 1727-8.
23. Moss HB, Chen CM, Yi HY. Subtypes of alcohol dependence in a nationally representative sample. Drug Alcohol Depend 2007; 91(2-3): 149-58.
24. Ait-Daoud N, Malcolm RJ, Johnson BA. An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addict Behav 2006; 31: 1628-49.
25. Miranda R Jr, MacKillop J, Monti PM, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 2008; 32(3): 489-97.
26. Kenna GA, McGeary JE, Swift RM. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 2. Am J Health-Syst Pharm 2004; 61: 2380-90.
27. Topamax [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc; Revised April 2008.
28. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41(suppl 1): S3-9.
29. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000; 41(Suppl 1): S35-9.
30. Dessirier JM, Simons CT, Carstens MI, et al. Psychophysical and neurobiological evidence that the oral sensation elicited by carbonated water is of chemogenic origin. Chem Senses 2000; 25: 277-84.
31. Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 1995; 19(1): 92-9.
32. Rubio G, Ponce G, Jiménez-Arriero MA, et al. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry 2004; 37(1): 37-40.
33. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298(14): 1641-51.
34. Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol 1995; 56(4): 423-32.
35. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate improves the physical health and quality of life of alcohol-dependent individuals: the US multi-site randomized controlled trial. Arch Intern Med 2008; 168(11): 1188-99.
36. National Institute of Mental Health. CGI: clinical global impressions. In: Guy W, Bonato RR, Eds. Manual for the ECDEU Assessment Battery, 2nd Revised Edition. Chevy Chase, MD: National Institute of Mental Health; 1970: 12.1-12.6.
37. Miller WR, Tonigan JS, Longabaugh R. The Drinker Inventory of Consequences (DrInC): an instrument for assessing adverse consequences of alcohol abuse. In: Mattson ME, Marshall LA, Eds. Project MATCH Monograph Series, Vol 4. NIH Publication No. 95-3911. Rockville, MD: National Institutes of Health; 1995.
38. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321-6.
39. McNair DM, Lorr M, Droppleman LF. Manual of the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service; 1971.
40. Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med 2005; 6: 41-4.
41. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 2004; 61(9): 905-12.
42. De Sousa, AA, De Sousa J, Kapoor H. An open randomized trial comparing disulfiam and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat 2008; 34: 460-3.
43. Flórez G, García-Portilla P, Alvarez S, et al. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol Clin Exp Res 2008; 32(7): 1251-9.
44. Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008; [Epub ahead of print].
45. Fernandez Miranda JJ, Marina González PA, Montes Pérez M, et al. Topiramate as add-on therapy in non-respondent alcohol dependant patients: a 12 month follow-up study. Actas Esp Psiquiatr 2007; 35(4): 236-42.
46. Biton V, Edwards KR, Montouris GD, et al. Topiramate titration and tolerability. Ann Pharmcother 2001; 35: 173-9.
47. Bootsma HPR, Coolen F, Aldenkamp AP. Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 2004; 5: 380-7.
48. Lee ST, Chu K, Park JE, et al. Paresthesia as a favorable predictor of migraine prophylaxis using topiramate. Eur J Neurol 2007; 14: 654-8.
49. Mula M, Anticonvulsants - antidepressants pharmacokinetic drug interactions: the role of the CYP450 system in psychopharmacology. Curr Drug Metab 2008; 9(8): 730-7.
50. Alapati A. Side effect profile on two different starting doses of topiramate [abstract]. Epilepsia 1999; 40(Suppl 1): S141-2.